LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today it has initiated enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of T4 endonuclease topical DNA repair enzyme and photolyase cream to reduce this DNA damage as measured through gene expression analysis. The study is being conducted in healthy volunteers and subjects with a history of skin cancer, at a single-site under Dr. Ronald L. Moy, past president of the American Academy of Dermatology and American Society for Dermatologic Surgery. The purpose of the study is to mimic DNA damage as seen with acute excessive sun exposure and determine if the use of DermTech’s proprietary non-invasive adhesive patch kits can detect this DNA damage through a panel of markers. The skin is then subsequently assessed to see if topical products can reduce this damage. Clinical study results are expected Q4 2018.
“The ability to assess and quantify RNA gene expression and DNA damage in the skin will give us a better way to rate sunscreens and medications that can reverse and prevent sun damage. This new methodology could revolutionize our application of sun damage prophylaxis and treatment regimens,” said Dr. Moy.
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit dermtech.com.